The Medical Letter - 2026
Search or Select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
January 5, 2026 (Issue 1745)  
  • Gepotidacin (Blujepa) — A New Antibiotic for Uncomplicated UTI   
    The FDA has approved gepotidacin (Blujepa – GSK), a triazaacenaphthylene bacterial type II topoisomerase inhibitor, for oral treatment of uncomplicated urinary tract infections (uUTI) in female patients...
  • Remibrutinib (Rhapsido) for Chronic Spontaneous Urticaria   
    The FDA has approved remibrutinib (Rhapsido – Novartis), an oral Bruton's tyrosine kinase (BTK) inhibitor, for treatment of chronic spontaneous urticaria in adults who remain symptomatic...
  • Drugs Past Their Expiration Date   
    Healthcare providers are often asked if drugs can be used past their expiration date. Because of legal restrictions and liability concerns, manufacturers do not sanction such use and usually do not...
  • In Brief: Alternatives to Bicillin L-A   
    On July 10, 2025 Pfizer issued a voluntary recall of certain lots of long-acting intramuscular (IM) benzathine penicillin G (Bicillin L-A) due to particulates identified during visual inspection. The CDC...
  • Correction   
    In our recent article titled Expanded Indication for PCSK9 Inhibitors (Med Lett Drugs Ther 2025; 67:201), the number needed to treat (NNT) to prevent one composite endpoint of myocardial infarction,...